PHASE-II CLINICAL-TRIAL WITH VINDESINE FOR REMISSION INDUCTION IN ACUTE-LEUKEMIA, BLASTIC CRISIS OF CHRONIC MYELOID-LEUKEMIA, LYMPHOSARCOMA, AND HODGKINS-DISEASE - ABSENCE OF CROSS-RESISTANCE WITH VINCRISTINE

Google Scholar
  • 1 January 1978
    • journal article
    • research article
    • Vol. 62  (5) , 805-809
Abstract
Vindesine, an analog of vinblastine and vincristine, was submitted to a phase II trial, the results of which are judged in terms of remission induction. A high proportion of remissions were obtained in [human] acute lymphoid leukemia and blastic crisis of chronic myeloid leukemia, and a few responses were registered in lymphosarcoma and Hodgkin''s disease. A continuous 48-h i.v. infusion may induce a remission where an i.v. push of the same dose failed. The most remarkable characteristic of vindesine is the absence of cross-resistance with vincristine as documented in acute lymphoid leukemia.